Quick Takeaways
- LTRN - Lantern Pharma Inc. has 11 insiders with reported activity on this page.
- Net insider value flow over the last year: -$1,000,580.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
Insider Transactions Reported by 11 Insiders of Lantern Pharma Inc.
- Symbol
- LTRN on Nasdaq
- Location
- Dallas, TX
What Changed
- Buy value: ; sell value: $1,000,580.
- Net share flow: -315,700.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$1,000,580.
Buys
$0
Shares: 0
Insiders: 0
Sells
$1,000,580
Shares: 315,700
Insiders: 2
Net
-$1,000,580
Shares: -315,700
Insiders: -2
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 315,700 | $0 | $1,000,580 | -$1,000,580 |
Lantern Pharma Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Leslie W. Kreis | 10%+ Owner | $3,344,781 | -$500,290 | -13% | Mixed | 13 Jun 2025 |
| Aaron G.l. Fletcher | 10%+ Owner | $3,344,781 | -$500,290 | -13% | Mixed | 13 Jun 2025 |
| Lee T. Schalop | Director | Mixed | 09 Jan 2026 | |||
| Maria-Luisa Maccecchini | Director | Mixed | 09 Jan 2026 | |||
| David S. Silberstein | Director | Mixed | 09 Jan 2026 | |||
| Panna Sharma | President & CEO, Director | Mixed | 19 Sep 2025 | |||
| Vijay Chandru | Director | Mixed | 09 Jan 2026 | |||
| David R. Margrave | Chief Financial Officer | Mixed | 18 Dec 2025 | |||
| Franklyn G. Prendergast | Director | Mixed | 04 Nov 2021 | |||
| Kishor G. Bhatia | Chief Scientific Officer | Mixed | 18 Dec 2025 | |||
| D. Jeffrey Keyser | Director | Mixed | 09 Jan 2026 |
Top shareholders of Lantern Pharma Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Aaron G.l. Fletcher |
3/4/5
|
10%+ Owner |
9.5%
|
1,075,952
|
$3,344,781 | -$500,290 | 13 Jun 2025 | |
| Leslie W. Kreis |
3/4/5
|
10%+ Owner |
9.5%
|
1,075,952
|
$3,344,781 | -$500,290 | 13 Jun 2025 | |
| BIOS Capital Management, LP |
13F
|
Company |
8.9%
|
1,009,507
|
$3,058,806 | — | 31 Dec 2025 | |
| Thomas A. Satterfield Jr. |
13D/G
|
— |
5.1%
|
570,000
|
$1,727,100 | $0 | 30 Mar 2026 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.4%
|
384,041
|
$1,163,644 | — | 31 Dec 2025 | |
| Bios Equity Partners, LP |
13D/G
|
Fletcher Aaron G.L. |
7.4%
|
834,752
|
$1,143,610 | -$171,625 | 16 Apr 2026 | |
| CM Management, LLC |
13F
|
Company |
2%
|
225,000
|
$681,750 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.98%
|
110,400
|
$334,512 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.86%
|
96,742
|
$293,191 | — | 31 Dec 2025 | |
| Voss Capital, LP |
13F
|
Company |
0.44%
|
50,000
|
$151,500 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.39%
|
44,253
|
$134,087 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.35%
|
39,110
|
$118,503 | — | 31 Dec 2025 | |
| NewEdge Advisors, LLC |
13F
|
Company |
0.34%
|
38,069
|
$115,354 | — | 31 Dec 2025 | |
| Westside Investment Management, Inc. |
13F
|
Company |
0.32%
|
35,900
|
$108,780 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.29%
|
32,895
|
$99,672 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.26%
|
28,820
|
$87,325 | — | 31 Dec 2025 | |
| HORIZON KINETICS ASSET MANAGEMENT LLC |
13F
|
Company |
0.24%
|
27,582
|
$83,573 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.23%
|
26,481
|
$80,237 | — | 31 Dec 2025 | |
| DAVENPORT & Co LLC |
13F
|
Company |
0.21%
|
23,814
|
$72,156 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.21%
|
23,652
|
$71,666 | — | 31 Dec 2025 | |
| Focus Partners Wealth |
13F
|
Company |
0.14%
|
15,982
|
$48,426 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.14%
|
15,589
|
$47,235 | — | 31 Dec 2025 | |
| CIBC Private Wealth Group LLC |
13F
|
Company |
0.14%
|
15,432
|
$46,759 | — | 31 Dec 2025 | |
| Cetera Investment Advisers |
13F
|
Company |
0.11%
|
12,228
|
$37,051 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.09%
|
10,627
|
$32,200 | — | 31 Dec 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.04%
|
4,072
|
$12,338 | — | 31 Dec 2025 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
0.02%
|
2,257
|
$6,838 | — | 31 Dec 2025 | |
| CURIO WEALTH, LLC |
13F
|
Company |
0.02%
|
2,000
|
$6,680 | — | 31 Dec 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.02%
|
2,143
|
$6,493 | — | 31 Dec 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.01%
|
1,475
|
$4,469 | — | 31 Dec 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
841
|
$2,548 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
601
|
$1,821 | — | 31 Dec 2025 | |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO |
13F
|
Company |
0%
|
500
|
$1,515 | — | 31 Dec 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
215
|
$651 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
69
|
$209 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
7
|
$21 | — | 31 Dec 2025 | |
| Key FInancial Inc |
13F
|
Company |
0%
|
2
|
$6 | — | 31 Dec 2025 | |
| D. Jeffrey Keyser |
3/4/5
|
Director |
—
class O/S missing
|
28,844
|
— | — | 09 Jan 2026 | |
| Maria-Luisa Maccecchini |
3/4/5
|
Director |
—
class O/S missing
|
21,152
|
— | — | 09 Jan 2026 | |
| David R. Margrave |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
20,000
|
— | — | 18 Dec 2025 | |
| Lee T. Schalop |
3/4/5
|
Director |
—
class O/S missing
|
18,460
|
— | — | 09 Jan 2026 | |
| David S. Silberstein |
3/4/5
|
Director |
—
class O/S missing
|
17,307
|
— | — | 09 Jan 2026 | |
| Vijay Chandru |
3/4/5
|
Director |
—
class O/S missing
|
17,307
|
— | — | 09 Jan 2026 | |
| Kishor G. Bhatia |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
10,000
|
— | — | 18 Dec 2025 | |
| Franklyn G. Prendergast |
3/4/5
|
Director |
—
class O/S missing
|
3,200
|
— | — | 04 Nov 2021 |
Recent Insider Transactions by Companies or Individuals for Lantern Pharma Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| D. Jeffrey Keyser | LTRN | Stock Option (Right to Buy) | Award | 53,844 | 28,844 | 09 Jan 2026 | Direct | |||
| Maria-Luisa Maccecchini | LTRN | Stock Option (Right to Buy) | Award | 46,152 | 25,000 | 09 Jan 2026 | Direct | |||
| Vijay Chandru | LTRN | Stock Option (Right to Buy) | Award | 42,307 | 25,000 | 09 Jan 2026 | Direct | |||
| Lee T. Schalop | LTRN | Stock Option (Right to Buy) | Award | 43,460 | 25,000 | 09 Jan 2026 | Direct | |||
| David S. Silberstein | LTRN | Stock Option (Right to Buy) | Award | 42,307 | 25,000 | 09 Jan 2026 | Direct | |||
| David R. Margrave | LTRN | Stock Option (Right to Buy) | Award | 20,000 | 20,000 | 18 Dec 2025 | Direct | |||
| Kishor G. Bhatia | LTRN | Stock Option (Right to Buy) | Award | 10,000 | 10,000 | 18 Dec 2025 | Direct | |||
| Lee T. Schalop | LTRN | Stock Option (Right to Buy) | Award | 5,000 | 5,000 | 19 Aug 2025 | Direct | |||
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -3.67% | $13,454 | $3.09 | -4,354 | 114,272 | 13 Jun 2025 | by Bios Fund II, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -3.67% | $43,934 | $3.09 | -14,218 | 373,178 | 13 Jun 2025 | By Bios Fund II QP, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -3.67% | $5,880 | $3.09 | -1,903 | 49,957 | 13 Jun 2025 | By Bios Fund II NT, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -3.67% | $38,066 | $3.09 | -12,319 | 323,335 | 13 Jun 2025 | By Bios Fund I, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -3.67% | $22,267 | $3.09 | -7,206 | 189,117 | 13 Jun 2025 | By Bios Fund I QP, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -3.67% | $13,454 | $3.09 | -4,354 | 114,272 | 13 Jun 2025 | By Bios Fund II, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -3.67% | $43,934 | $3.09 | -14,218 | 373,178 | 13 Jun 2025 | By Bios Fund II QP, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -3.67% | $5,880 | $3.09 | -1,903 | 49,957 | 13 Jun 2025 | By Bios Fund II NT, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -3.67% | $38,066 | $3.09 | -12,319 | 323,335 | 13 Jun 2025 | By Bios Fund I, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -3.67% | $22,267 | $3.09 | -7,206 | 189,117 | 13 Jun 2025 | By Bios Fund I QP, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -5.27% | $22,311 | $3.38 | -6,601 | 118,626 | 12 Jun 2025 | By Bios Fund II, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -5.27% | $72,863 | $3.38 | -21,557 | 387,396 | 12 Jun 2025 | By Bios Fund II QP, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -5.27% | $9,755 | $3.38 | -2,886 | 51,860 | 12 Jun 2025 | By Bios Fund II NT, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -5.27% | $63,132 | $3.38 | -18,678 | 335,654 | 12 Jun 2025 | By Bios Fund I, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -5.27% | $36,926 | $3.38 | -10,925 | 196,323 | 12 Jun 2025 | By Bios Fund I QP, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -5.27% | $22,311 | $3.38 | -6,601 | 118,626 | 12 Jun 2025 | By Bios Fund II, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -5.27% | $72,863 | $3.38 | -21,557 | 387,396 | 12 Jun 2025 | By Bios Fund II QP, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -5.27% | $9,755 | $3.38 | -2,886 | 51,860 | 12 Jun 2025 | By Bios Fund II NT, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -5.27% | $63,132 | $3.38 | -18,678 | 335,654 | 12 Jun 2025 | By Bios Fund I, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -5.27% | $36,926 | $3.38 | -10,925 | 196,323 | 12 Jun 2025 | By Bios Fund I QP, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -0.08% | $350 | $3.40 | -103 | 125,227 | 11 Jun 2025 | By Bios Fund II, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -0.08% | $1,149 | $3.40 | -338 | 408,953 | 11 Jun 2025 | By Bios Fund II QP, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -0.08% | $153 | $3.40 | -45 | 54,746 | 11 Jun 2025 | By Bios Fund II NT, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -0.08% | $996 | $3.40 | -293 | 354,332 | 11 Jun 2025 | By Bios Fund I, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -0.08% | $581 | $3.40 | -171 | 207,248 | 11 Jun 2025 | By Bios Fund I QP, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -0.08% | $350 | $3.40 | -103 | 125,227 | 11 Jun 2025 | By Bios Fund II, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -0.08% | $1,149 | $3.40 | -338 | 408,953 | 11 Jun 2025 | By Bios Fund II QP, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -0.08% | $153 | $3.40 | -45 | 54,746 | 11 Jun 2025 | By Bios Fund II NT, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -0.08% | $996 | $3.40 | -293 | 354,332 | 11 Jun 2025 | By Bios Fund I, LP |
| Leslie W. Kreis | LTRN | Common Stock | Sale | -0.08% | $581 | $3.40 | -171 | 207,248 | 11 Jun 2025 | By Bios Fund I QP, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | $6.8 | $3.40 | -2 | 125,330 | 10 Jun 2025 | By Bios Fund II, LP | |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | $17 | $3.40 | -5 | 409,291 | 10 Jun 2025 | By Bios Fund II QP, LP | |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | $3.4 | $3.40 | -1 | 54,791 | 10 Jun 2025 | By Bios Fund II NT, LP | |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | $17 | $3.40 | -5 | 354,625 | 10 Jun 2025 | By Bios Fund I, LP | |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | $10.2 | $3.40 | -3 | 207,419 | 10 Jun 2025 | By Bios Fund I QP, LP | |
| Leslie W. Kreis | LTRN | Common Stock | Sale | $6.8 | $3.40 | -2 | 125,330 | 10 Jun 2025 | By Bios Fund II, LP | |
| Leslie W. Kreis | LTRN | Common Stock | Sale | $17 | $3.40 | -5 | 409,291 | 10 Jun 2025 | By Bios Fund II QP, LP | |
| Leslie W. Kreis | LTRN | Common Stock | Sale | $3.4 | $3.40 | -1 | 54,791 | 10 Jun 2025 | By Bios Fund II NT, LP | |
| Leslie W. Kreis | LTRN | Common Stock | Sale | $17 | $3.40 | -5 | 354,625 | 10 Jun 2025 | By Bios Fund I, LP | |
| Leslie W. Kreis | LTRN | Common Stock | Sale | $10.2 | $3.40 | -3 | 207,419 | 10 Jun 2025 | By Bios Fund I QP, LP | |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -1.72% | $6,663 | $3.03 | -2,199 | 125,332 | 29 May 2025 | By Bios Fund II, LP |
| Aaron G.l. Fletcher | LTRN | Common Stock | Sale | -1.72% | $21,755 | $3.03 | -7,180 | 409,296 | 29 May 2025 | By Bios Fund II QP, LP |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.